Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Lung cancer is a major public health problem throughout the world. Among the most frequent cancer types (prostate, breast, colorectal, stomach, lung), lung cancer is the leading cause of cancer-related deaths worldwide. Among the two major subtypes of small cell lung cancer and nonsmall cell lung cancer (NSCLC), 85% of tumors belong to the NSCLC histological types. Small cell lung cancer is associated with the shortest survival time. Although tobacco smoking has been recognized as the major risk factor for lung cancer, there is a great interindividual and interethnic difference in risk of developing lung cancer given exposure to similar environmental and lifestyle factors. This may indicate that in addition to chemical and environmental factors, genetic variations in the genome may contribute to risk modification. A common type of genetic variation in the genome, known as single nucleotide polymorphism, has been found to be associated with susceptibility to lung cancer. Interestingly, many of these polymorphisms are found in the genes that regulate major pathways of carcinogen metabolism (cytochrome P450 genes), detoxification (glutathione S-transferases), adduct removal (DNA repair genes), cell growth/apoptosis (TP53/MDM2), the immune system (cytokines/chemokines), and membrane receptors (nicotinic acetylcholine and dopaminergic receptors). Some of these polymorphisms have been shown to alter the level of mRNA, and protein structure and function. In addition to being susceptibility markers, several of these polymorphisms are emerging to be important for response to chemotherapy/radiotherapy and survival of patients. Therefore, it is hypothesized that single nucleotide polymorphisms will be valuable genetic markers in individual-based prognosis and therapy in future. Here we will review some of the most important single nucleotide polymorphisms in the metabolic pathways that may modulate susceptibility, prognosis, and therapy in NSCLC.

[1]  Kari Chansky,et al.  The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  D. Lin,et al.  Cyclooxygenase-2 Genetic Variants Are Associated with Survival in Unresectable Locally Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[3]  Leah E. Mechanic,et al.  Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. , 2011, Journal of the National Cancer Institute.

[4]  F. Bray,et al.  Survival of patients diagnosed with cancer in the Nordic countries up to 1999–2003 followed to the end of 2006. A critical overview of the results , 2010, Acta oncologica.

[5]  J. Schneider,et al.  Cyp1B1 mRNA expression in correlation to cotinine levels with respect to the Cyp1B1 L432V gene polymorphism , 2010, European Journal of Epidemiology.

[6]  F. Khuri,et al.  Sex differences in survival in non-small cell lung cancer patients 1974-1998. , 2004, Acta oncologica.

[7]  S. Zienolddiny,et al.  Differential binding of proteins to the IL1B -31 T/C polymorphism in lung epithelial cells. , 2007, Cytokine.

[8]  S. Senogles.  D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69 , 2007, Anti-cancer drugs.

[9]  J. Ioannidis,et al.  A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. , 2009, Journal of the National Cancer Institute.

[10]  A. Valachis,et al.  Translational Medicine and Reliability of Single-Nucleotide Polymorphism Studies: Can We Believe in SNP Reports or Not? , 2011, International journal of medical sciences.

[11]  Simon Heath,et al.  Lung cancer susceptibility locus at 5p15.33 , 2008, Nature Genetics.

[12]  Yongtang Jin,et al.  Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on non small cell lung cancer: a hospital-based case-control study in China , 2010, BMC Cancer.

[13]  M. Gielen,et al.  maximally attained lung function -174G/C SNP and IL6 Association between the , 2011 .

[14]  Darren R. Brenner,et al.  Previous Lung Diseases and Lung Cancer Risk: A Systematic Review and Meta-Analysis , 2011, PloS one.

[15]  S. Senogles.  D2s dopamine receptor mediates phospholipase D and antiproliferation , 2003, Molecular and Cellular Endocrinology.

[16]  Y. Nakanishi,et al.  EPHX1 Polymorphisms and the Risk of Lung Cancer: A HuGE Review , 2006, Epidemiology.

[17]  S. Senan,et al.  Stage I Non-small Cell Lung Cancer (NSCLC) in Patients Aged 75 Years and Older: Does Age Determine Survival After Radical Treatment? , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  D. Parkin,et al.  The role of cancer registries in cancer control , 2008, International Journal of Clinical Oncology.

[19]  M. Spitz,et al.  Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. , 2007, Cancer research.

[20]  K. Hemminki,et al.  MDM2 SNP309 and cancer risk: a combined analysis. , 2007, Carcinogenesis.

[21]  Yi-long Wu,et al.  CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. , 2011, European Journal of Cancer.

[22]  J. Ferlay,et al.  Fifty years of cancer incidence: CI5 I–IX , 2010, International journal of cancer.

[23]  H. Pyo,et al.  Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated , 2010, Molecular Cancer.

[24]  Ji-Hong Pan,et al.  CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer , 2007, Acta oncologica.

[25]  D. Phillips,et al.  Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. , 2005, Lung cancer.

[26]  S. Zienolddiny,et al.  A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. , 2011, Lung cancer.

[27]  D. Christiani.  The environment and the lung: detection, prevention, and mechanism of disease. , 2010, Proceedings of the American Thoracic Society.

[28]  Feng Xu,et al.  EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features , 2011, Journal of experimental & clinical cancer research : CR.

[29]  H. Bartsch,et al.  Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  P. Paré,et al.  Associations of IL6 polymorphisms with lung function decline and COPD , 2009, Thorax.

[31]  Franco Berrino,et al.  Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. , 2007, The Lancet. Oncology.

[32]  D. Christiani,et al.  Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib , 2008, The Pharmacogenomics Journal.

[33]  D. Hatsukami,et al.  Immediate consequences of cigarette smoking: rapid formation of polycyclic aromatic hydrocarbon diol epoxides. , 2011, Chemical research in toxicology.

[34]  D. Stewart.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. , 2010, Critical reviews in oncology/hematology.

[35]  Howard L McLeod,et al.  Copy number variants in pharmacogenetic genes. , 2011, Trends in molecular medicine.

[36]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[37]  X. Mariette,et al.  Functional study of TNF-α promoter polymorphisms: literature review and meta-analysis. , 2011, European cytokine network.

[38]  S. Gelmini,et al.  Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers , 2011, Clinical chemistry and laboratory medicine.

[39]  F. Guengerich,et al.  Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. , 1996, Carcinogenesis.

[40]  G. Fontanini,et al.  Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. , 2008, Oncology reports.

[41]  Zoe Wainer,et al.  Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  K. Sabapathy,et al.  Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore , 2010, BMC Cancer.

[43]  E. Brambilla,et al.  Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors , 2002, Oncogene.

[44]  D. Phillips,et al.  Polycyclic Aromatic Hydrocarbon (PAH) Exposure and DNA Adduct Semi-Quantitation in Archived Human Tissues , 2011, International journal of environmental research and public health.

[45]  K. Sigel,et al.  Effect of Age on Survival of Clinical Stage I Non-Small-Cell Lung Cancer , 2009, Annals of Surgical Oncology.

[46]  Kwang-Kyun Park,et al.  Polymorphisms in genes coding for enzymes metabolizing smoking-derived substances and the risk of periodontitis. , 2004, Journal of clinical periodontology.

[47]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[48]  M. Christmann,et al.  O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. , 2011, Biochimica et biophysica acta.

[49]  Rui Ju,et al.  Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole. , 2012, European journal of cancer.

[50]  Jorge Zerón-Medina,et al.  Single-nucleotide polymorphisms in the p53 signaling pathway. , 2010, Cold Spring Harbor perspectives in biology.

[51]  L. Bierut,et al.  The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European–Americans , 2011, Pharmacogenetics and genomics.

[52]  R. Rosenfeld.  Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[53]  Ya‐Wen Cheng,et al.  Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors , 2010, Annals of Surgical Oncology.

[54]  M. Tang,et al.  Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. , 2000, Journal of the National Cancer Institute.

[55]  L. Coussens,et al.  Cancer: An inflammatory link , 2004, Nature.

[56]  Weibo Liang,et al.  IL-8 -251A/T polymorphism is associated with decreased cancer risk among population-based studies: evidence from a meta-analysis. , 2010, European journal of cancer.

[57]  M. Yamamoto,et al.  Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. , 1996, Cancer research.

[58]  P. Birembaut,et al.  Nicotinic acetylcholine receptors and predisposition to lung cancer , 2011, Current opinion in oncology.

[59]  Robert W Sobol,et al.  Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. , 2011, Antioxidants & redox signaling.

[60]  J. Gasperino.  Gender is a risk factor for lung cancer. , 2011, Medical hypotheses.

[61]  Christoph Plass,et al.  Lung cancer epigenetics and genetics , 2008, International journal of cancer.

[62]  H. Puchta,et al.  Gene regulation in response to DNA damage. , 2012, Biochimica et biophysica acta.

[63]  P. Brennan,et al.  Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. , 2005, American journal of epidemiology.

[64]  Arne Klungland,et al.  DNA Repair in Mammalian Cells : Base excision repair: the long and short of it (Multi-author Review) , 2009 .

[65]  Heung Tae Kim,et al.  DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma , 2011, Cancer.

[66]  David Ryberg,et al.  Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer. , 2007, Lung cancer.

[67]  V. Pankratz,et al.  Systematic Evaluation of Genetic Variants in Three Biological Pathways on Patient Survival in Low-Stage Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[68]  J. Wakefield,et al.  Sequence Variants of NAT1 and NAT2 and Other Xenometabolic Genes and Risk of Lung and Aerodigestive Tract Cancers in Central Europe , 2008, Cancer Epidemiology Biomarkers & Prevention.

[69]  M. Janssen-Heijnen,et al.  Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome. , 2009, Interactive cardiovascular and thoracic surgery.

[70]  Wang Yang.  DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy , 2010 .

[71]  J. Robert,et al.  Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models , 2010, Molecular Cancer Therapeutics.

[72]  U. Vogel,et al.  Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. , 2008, Mutation research.

[73]  Shun Lu,et al.  The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. , 2011, Mutagenesis.

[74]  R J Edwards,et al.  Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon‐DNA adduct formation in bronchoalveolar macrophages of smokers and non‐smokers , 2000, International journal of cancer.

[75]  B. Nordestgaard,et al.  Genetically Lowered Microsomal Epoxide Hydrolase Activity and Tobacco-Related Cancer in 47,000 Individuals , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[76]  Federico González-Aragoneses,et al.  Multicenter analysis of survival and prognostic factors in pathologic stage I non-small-cell lung cancer according to the new 2009 TNM classification. , 2011, Archivos de bronconeumologia.

[77]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[78]  K. Hiom.  Coping with DNA double strand breaks. , 2010, DNA repair.

[79]  E. Fontaine,et al.  Aspirin and non-small cell lung cancer resections: effect on long-term survival. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[80]  Vidar Skaug,et al.  Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts , 2006, International journal of cancer.

[81]  C. Shih,et al.  Lack of Evidence of Association of p21WAF1/CIP1 Polymorphism with Lung Cancer Susceptibility and Prognosis in Taiwan , 2000, Japanese journal of cancer research : Gann.

[82]  E. Gallardo,et al.  Prognostic implications of miR‐16 expression levels in resected non‐small‐cell lung cancer , 2011, Journal of surgical oncology.

[83]  P. Brennan,et al.  Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. , 2009, Cancer letters.

[84]  S. Bojesen,et al.  Nicotinic acetylcholine receptor polymorphism, smoking behavior, and tobacco-related cancer and lung and cardiovascular diseases: a cohort study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  J. Bai,et al.  MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis. , 2011, Journal of genetics and genomics = Yi chuan xue bao.

[86]  D. Campa,et al.  A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. , 2008, Carcinogenesis.

[87]  Jasna Banković,et al.  Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. , 2011, Translational research : the journal of laboratory and clinical medicine.

[88]  R. Figlin,et al.  Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape , 2010, Molecular Cancer Therapeutics.

[89]  Hongbing Shen,et al.  Smoking, DNA repair capacity and risk of nonsmall cell lung cancer , 2003, International journal of cancer.

[90]  D. Neal.  PSA testing for prostate cancer improves survival--but can we do better? , 2010, The Lancet. Oncology.

[91]  Akira Mogi,et al.  TP53 Mutations in Nonsmall Cell Lung Cancer , 2011, Journal of biomedicine & biotechnology.

[92]  D. Mavroudis,et al.  DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. , 2009, Clinical lung cancer.

[93]  Leah E. Mechanic,et al.  Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. , 2007, Journal of the National Cancer Institute.

[94]  G. Iliakis,et al.  Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. , 2011, Mutation research.

[95]  H. Sasaki,et al.  A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer , 2008, Journal of Cancer Research and Clinical Oncology.

[96]  Vidar Skaug,et al.  Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. , 2003, Carcinogenesis.

[97]  K. Sabapathy,et al.  Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs , 2005, Clinical Cancer Research.

[98]  R. Houlston,et al.  The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. , 2009, Carcinogenesis.

[99]  R. Brigelius-Flohé,et al.  Glutathione peroxidases in different stages of carcinogenesis. , 2009, Biochimica et biophysica acta.

[100]  K. Stefánsson,et al.  Association of a novel functional promoter variant (rs2075533 C>T) in the apoptosis gene TNFSF8 with risk of lung cancer--a finding from Texas lung cancer genome-wide association study. , 2011, Carcinogenesis.

[101]  A. Schetter,et al.  Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. , 2010, Carcinogenesis.

[102]  S. Zienolddiny,et al.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.

[103]  K. Straif,et al.  Occupational exposure to organic dust increases lung cancer risk in the general population , 2011, Thorax.

[104]  J. Bai,et al.  Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis , 2008, Journal of Human Genetics.

[105]  J. Smith,et al.  Influence of sex on lung cancer histology, stage, and survival in a midwestern United States tumor registry. , 2005, Clinical lung cancer.

[106]  A. Mariotto,et al.  Improved estimates of cancer-specific survival rates from population-based data. , 2010, Journal of the National Cancer Institute.

[107]  H. Bartsch,et al.  Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. , 1995, Pharmacogenetics.

[108]  H. Sugimura,et al.  Genetic susceptibility to lung cancer. , 2011, Frontiers in bioscience.

[109]  T. Illig,et al.  Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer , 2007, Pharmacogenetics and genomics.

[110]  Hongbing Shen,et al.  Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population , 2006, International journal of cancer.

[111]  M. Iscan,et al.  Polymorphisms of cytochrome P450 1A1, glutathione S-transferases M1 and T1 in a Turkish population. , 2004, Toxicology letters.

[112]  J. Schneider,et al.  RNA expressions of AHR, ARNT and CYP1B1 are influenced by AHR Arg554Lys polymorphism. , 2011, Molecular genetics and metabolism.

[113]  H. Lee,et al.  Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients , 2006, Medical oncology.

[114]  S. Alpar,et al.  CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. , 2010, Neoplasma.

[115]  K. Sabapathy,et al.  Trp53-dependent DNA-repair is affected by the codon 72 polymorphism , 2006, Oncogene.

[116]  Polycarpos Pissis,et al.  Role of oxidative stress and DNA damage in human carcinogenesis. , 2011, Mutation research.

[117]  R. Catarino,et al.  Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy , 2010, Cancer Chemotherapy and Pharmacology.

[118]  L. Landi,et al.  Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR , 2011, Nature Reviews Clinical Oncology.

[119]  A. Levine,et al.  A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans , 2007, Oncogene.

[120]  R. Altman,et al.  Databases in the area of pharmacogenetics , 2011, Human mutation.

[121]  Ping Yang,et al.  Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. , 2004, The Annals of thoracic surgery.

[122]  A. Klungland,et al.  Oxidative damage to purines in DNA: role of mammalian Ogg1. , 2007, DNA repair.

[123]  E. Riboli,et al.  Single-nucleotide polymorphisms (5p15.33, 15q25.1, 6p22.1, 6q27 and 7p15.3) and lung cancer survival in the European Prospective Investigation into Cancer and Nutrition (EPIC). , 2011, Mutagenesis.

[124]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[125]  W. Xu,et al.  The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. , 2010, Lung cancer.

[126]  W. Tan,et al.  Combined Effect of Genetic Polymorphisms in P53, P73, and MDM2 on Non-small Cell Lung Cancer Survival , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[127]  S. Zienolddiny,et al.  A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. , 2009, Carcinogenesis.

[128]  Elisabeth Brambilla,et al.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.

[129]  Vidar Skaug,et al.  The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non–Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts , 2011, Clinical Cancer Research.

[130]  D. Phillips,et al.  Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells. , 2011, Lung cancer.

[131]  S. Zienolddiny,et al.  Allele-specific induction of IL1B -31T/C promoter polymorphism by lung carcinogens. , 2008, Mutation research.

[132]  M. F. White,et al.  The evolution and mechanisms of nucleotide excision repair proteins. , 2011, Research in microbiology.

[133]  A. Okamoto,et al.  A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. , 2001, Biochemical and biophysical research communications.

[134]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[135]  Dong Sun Kim,et al.  Polymorphisms in the caspase-8 gene and the risk of lung cancer. , 2006, Cancer genetics and cytogenetics.

[136]  A. Levine,et al.  MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.

[137]  B. Mittal,et al.  Association of Functionally Important Polymorphism of Microsomal Epoxide Hydrolase Gene (EPHX1) With Lung Cancer Susceptibility , 2011, Cancer investigation.

[138]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[139]  S. Ren,et al.  Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. , 2012, Lung Cancer.

[140]  L. Lazzeroni,et al.  Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5‐A3‐B4) predict severity of nicotine addiction and response to smoking cessation therapy , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[141]  M. Ingelman-Sundberg,et al.  Genetic polymorphism and toxicology--with emphasis on cytochrome p450. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[142]  Chi-Ying F. Huang,et al.  Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[143]  K. Stefánsson,et al.  analysis of single nucleotide polymorphisms of 125 DNA repair genes in the exas genome-wide association study of lung cancer with a replication for the RCC 4 SNPs , 2011 .

[144]  W. Tan,et al.  Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis , 2008, Clinical Cancer Research.

[145]  C. Sarkar,et al.  O6-Methylguanine DNA Methyltransferase Gene Promoter Methylation Status in Gliomas and Its Correlation With Other Molecular Alterations: First Indian Report With Review of Challenges for Use in Customized Treatment , 2010, Neurosurgery.

[146]  D. Cescon,et al.  Pharmacogenetic and Germline Prognostic Markers of Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[147]  K. Yoshimasu,et al.  Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A meta-analysis , 2007, International journal of medical sciences.

[148]  Hongbing Shen,et al.  MDM2 SNP309 contributes to non‐small cell lung cancer survival in Chinese , 2011, Molecular carcinogenesis.

[149]  J. Agúndez.  Polymorphisms of human N-acetyltransferases and cancer risk. , 2008, Current drug metabolism.

[150]  R. Welsh,et al.  Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. , 2010, Lung cancer.

[151]  Y. Nakanishi,et al.  Lung Cancer Risk and Genetic Polymorphisms in DNA Repair Pathways: A Meta-Analysis , 2010, Journal of nucleic acids.

[152]  Li-ke Yu,et al.  ERCC2/XPD Polymorphisms and Lung Cancer Risk , 2011 .

[153]  Nicole Benoit,et al.  p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. , 2003, Journal of the National Cancer Institute.

[154]  Magnus Ingelman-Sundberg,et al.  The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects , 2010, Human Genomics.

[155]  P. Dickman,et al.  Temporal trends in non-small cell lung cancer survival in Sweden , 2007, British Journal of Cancer.

[156]  E. Bowman,et al.  MDM2 SNP309 and SNP354 Are Not Associated with Lung Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[157]  H. Sasaki,et al.  Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. , 2011, The Journal of surgical research.

[158]  D. Campa,et al.  Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. , 2006, Carcinogenesis.

[159]  F. Canzian,et al.  Polymorphisms of the interleukin‐1 β gene are associated with increased risk of non‐small cell lung cancer , 2004, International journal of cancer.

[160]  N. Roodi,et al.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. , 2000, Cancer research.

[161]  M. Dewhirst,et al.  Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer , 2010, Medical oncology.

[162]  R. Hitt,et al.  DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  S. Zienolddiny,et al.  Frequency of TP53 Mutations in Relation to Arg72Pro Genotypes in Non–Small Cell Lung Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[164]  E. Giovannetti,et al.  Molecular Cancer Therapeutics Association of Polymorphisms in AKT 1 and EGFR with Clinical Outcome and Toxicity in Non – Small Cell Lung Cancer Patients Treated with Gefitinib , 2010 .

[165]  Joe Y. Chang,et al.  Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer , 2010, PloS one.

[166]  S. Motoyama,et al.  The CRP 1846T/T genotype is associated with a poor prognosis in patients with non-small cell lung cancer , 2010, Tumor Biology.

[167]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[168]  J. Krebs,et al.  Five repair pathways in one context: chromatin modification during DNA repair. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[169]  Yi Shi,et al.  Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis , 2011, Medical oncology.

[170]  Paolo Boffetta,et al.  Genetics of lung-cancer susceptibility. , 2011, The Lancet. Oncology.

[171]  J. Cunningham,et al.  A Rigorous and Comprehensive Validation: Common Genetic Variations and Lung Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[172]  P. Vineis,et al.  Is there evidence of involvement of DNA repair polymorphisms in human cancer? , 2012, Mutation research.

[173]  David C Christiani,et al.  Genome-wide analysis of survival in early-stage non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  A. Begg,et al.  Targeting base excision repair as a sensitization strategy in radiotherapy. , 2010, Seminars in radiation oncology.

[175]  Hongbing Shen,et al.  Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. , 2010, Carcinogenesis.

[176]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[177]  F. Khuri,et al.  Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism , 2009, Molecular Cancer Therapeutics.

[178]  D. Kwiatkowski,et al.  Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. , 2001, American journal of human genetics.

[179]  Y. Maehara,et al.  Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. , 2010, Lung cancer.

[180]  S. Zienolddiny,et al.  The CASPASE-8 Insertion/Deletion Polymorphism and Risk of Non-small Cell Lung Cancer , 2010 .

[181]  A. Schetter,et al.  Circulating micro‐RNA expression profiles in early stage nonsmall cell lung cancer , 2012, International journal of cancer.